New insider activity at Hims & Hers Health ( (HIMS) ) has taken place on August 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CLO Soleil Boughton recently sold 2,571 shares of Hims & Hers Health stock, amounting to a total transaction value of $114,486.
Recent Updates on HIMS stock
In recent developments, Hims & Hers Health has experienced a decline in stock price amidst several significant events. The company is under investigation by the Federal Trade Commission (FTC) for its business practices, particularly concerning subscription cancellations, which has been ongoing for over a year. This investigation has contributed to a cautious outlook from analysts. Additionally, Truist has lowered its price target for Hims & Hers, citing concerns about the company’s revenue mix and growth prospects, despite expectations of increased GLP-1 related revenues. Morgan Stanley also highlighted a decline in app downloads, raising questions about the company’s core business growth strategy. These factors have collectively influenced the stock’s performance and analysts’ perspectives.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Neutral.
Hims & Hers Health demonstrates strong financial performance and strategic growth initiatives, particularly in international expansion and technology. However, high leverage, declining cash flow, and bearish technical indicators present significant risks. The stock’s high valuation further tempers its attractiveness.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
YTD Price Performance: 70.60%
Average Trading Volume: 38,435,228
Technical Sentiment Signal: Buy
Current Market Cap: $9.72B